aibioTuHURA Biosciences borrows $1,500,000 under Parkview revolving facility
Tickers HURA
The company borrowed $1,500,000 on September 2, 2026 under a loan agreement with Parkview Holdings One LLC. The facility allows up to $50 million and matures on April 21, 2031.
Key facts
- Company
- TuHURA Biosciences, Inc. (NASDAQ: HURA)
- News type
- Debt Financing
- Primary source
- TuHURA Biosciences, Inc. 8-K (2026-09-04)
TuHURA Biosciences, Inc. (Nasdaq: HURA) received and borrowed an additional draw of $1,500,000 under a revolving credit facility with Parkview Holdings One LLC on September 2, 2026, according to a Form 8-K filed on September 4, 2026. Parkview is the lender. The filing names no placement agent, underwriter or advisor for the facility.
Facility terms and warnings
The company entered into the Loan Agreement with Parkview on April 21, 2026. The facility matures on April 21, 2031 and provides maximum loan availability of $50 million. The filing does not state an interest rate for the draw or describe any collateral. The full agreement was filed as Exhibit 4.1 to a Form 8-K filed on April 22, 2026.
The company said it expects to use the funds for general corporate purposes. The 8-K also warns that the company may be unable to satisfy conditions to drawdown or to maintain compliance with the loan terms. It says funds available under the agreement may be insufficient to fund operations and development programs as anticipated. It flags potential conflicts of interest arising from the loan with an affiliate of the company's largest stockholder. The facility is a source of money only while the company meets those conditions.
The company and its pipeline
TuHURA describes itself as a Phase 3 clinical stage immuno-oncology company. Its lead candidate, IFx2.0, is designed to overcome primary resistance to checkpoint inhibitors. In June 2025 the company began a single randomized, placebo-controlled Phase 3 registration trial of IFx2.0 as adjunctive therapy to Keytruda, pembrolizumab, in first-line advanced or metastatic Merkel cell carcinoma, under the FDA's accelerated approval pathway. The trial enrolls checkpoint inhibitor naive patients, and the company is relying on a single registration trial, so approval would rest on one study.
The company also acquired rights to TBS-2025, a VISTA-inhibiting antibody, through its June 30, 2025 acquisition of Kineta, Inc. It plans a Phase 1b/2 trial of that antibody in relapsed or refractory mutated NPM1 acute myeloid leukemia. The company traces its current form to an October 18, 2024 reverse merger with Kintara Therapeutics, which was then renamed TuHURA Biosciences. The Kineta merger issued about 4 million shares of common stock to former Kineta stockholders, and the 10-K says those holders also received about 1,129,880 more shares in December 2025 under the same agreement.
The company also is developing first-in-class bi-functional, bi-specific antibody-drug conjugates against the delta opioid receptor on myeloid-derived suppressor cells.
Losses and cash
The company reported no revenue in 2025 or 2024. Research and development expense rose to $20.5 million in 2025 from $13.3 million in 2024. The net loss widened to $30.1 million in 2025 from $21.7 million in 2024, and cash used in operations rose to $27.6 million from $14.7 million. Year-end cash was $12.7 million in 2024 and $3.6 million in 2025, according to the company's filings.
Cash and cash equivalents were $995,977 at June 30, 2026, so the $1,500,000 draw is larger than the cash the company reported at that date.
Further draws depend on the conditions in the Loan Agreement, which the 8-K does not list. The Phase 3 trial is the company's main regulatory step. Any further borrowing would add to a facility whose drawdown conditions the 8-K lists as a risk the company may not meet.